Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer .

Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer . Am Soc Clin Oncol Educ Book. 2013.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.